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Abstract
The pathogenesis of infl ammatory bowel disease (IBD) 
is only partially understood. Various environmental 
and host (e.g. genetic-, epithelial-, immune and non-
immune) factors are involved. It is a multifactorial 
polygenic disease with probable genetic heterogeneity. 
Some genes are associated with IBD itself, while others 
increase the risk of ulcerative colitis (UC) or Crohn’
s disease (CD) or are associated with disease location 
and/or behaviour. This review addresses recent advances 
in the genetics of IBD. The article discusses the current 
information on the crosstalk between microbial and 
genetic factors (e.g. NOD2/CARD15, SLC22A46A5 and 
DLG5). The genetic data acquired in recent years help in 
understanding the pathogenesis of IBD and can identify a 
number of potential targets for therapeutic intervention. 
In the future, genetics may help more accurately diagnose 
and predict disease course in IBD. 
© 2006 The WJG Press. All rights  reserved.
Key words: Inflammatory bowel disease; Ulcerative 
colitis; Crohn’s disease; Pathogenesis; Microbial factors; 
Genetics; NOD2/CARD15; SLC22A4/A5; DLG5
Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current 
concept on the pathogenesis of inflammatory bowel 
disease-crosstalk between genetic and microbial factors: 
Pathogenic bacteria and altered bacterial sensing or changes 
in mucosal integrity take “toll”? World J Gastroenterol 2006; 
12(12):1829-1841 
 http://www.wjgnet.com/1007-9327/12/1829.asp 
INTRODUCTION
There has been a sharp increase in the incidence of  
inflammatory bowel disease (IBD) in the late 1900s in 
Western countries as well as in some Eastern parts of  
Europe and North America[1-3]. Both Crohn’s disease 
(CD) and ulcerative colitis (UC) stem possibly from a 
common mechanism with an exact etiology that remains 
obscure[4,5]. Crohn’s disease manifests itself  as a chronic 
granulomatous infl ammation of  the gastrointestinal tract 
capable of  affecting its entire length with the presence 
of  “skip” lesions[6,7]. It preferentially affects the terminal 
ileum, as was originally described by Crohn et al [8]. 
Ulcerative colitis, on the contrary, presents as a continuous 
inflammatory lesion affecting the rectum and colon, 
lacking granulomatous characteristics.
    IBD are multifactorial, polygenic diseases with probable 
genetic heterogeneity. According to this hypothesis, 
different genetic backgrounds may explain the various 
clinical patterns of  the disease[4,5]. In addition to genetic 
predisposition, various environmental and host factors 
(e.g. genetic-, epithelial-, immune and non-immune) 
play a major role in the pathogenesis of  IBD. Extensive 
heterogeneity is observed in terms of  presentation, 
extraintestinal manifestations and location in CD, while 
behavior and response to treatment are heterogeneous in 
both CD and UC[9]. Furthermore, it is now undisputed that 
enteric bacterial fl ora play a key role in the pathogenesis 
of  IBD, both in UC and in CD. The exact mechanism 
by which the intestinal mucosa loses tolerance to its 
bacterial neighbors remains elusive. The role of  host 
genetic regulation of  the innate immune response in the 
pathogenesis of  CD has been brought to sharp focus by 
the identifi cation of  the NOD2 (CARD15) mutations.
    The genetic aspect of  research is quite focused on nu-
merous chromosomal loci. The environmental contribu-
tors are diverse and an “infectious origin” of  infl amma-
tory bowel disease has not been confi rmed. This review 
describes the various environmental, immunologic and 
genetic components leading to the manifestation of  in-
fl ammatory bowel disease.
www.wjgnet.com
REVIEW 
MICROBIAL FACTORS: ARE PATHOGENIC 
BACTERIA AND/OR ALTERED PERCEPTION 
OF NORMAL FLORA THE KEYS IN THE 
BREAKDOWN OF TOLERANCE?
The normal intestine encounters a high concentration of  
foreign antigens, bacteria and food. In the stomach and 
proximal small intestine, secretion of  acid and bile, phasic 
‘housekeeping’ motility patterns hinder colonization. How-
ever, the number of  bacteria dramatically increases in the 
distal small intestine to an estimated 1010 - 1012 bacterial 
cells/g content in the colon, which contribute to 60% of  
the faecal mass[10]. More than 400-500 species of  bacteria 
are represented, belonging to 30 genera. Although this 
antigenic load is separated from the largest complement 
of  lymphocytes in the body (gut associated lymphoid tis-
sue, GALT) by only a single layer of  polarised intestinal 
epithelium, most people do not have an immune response 
to foreign antigens and interaction between the mucosal 
immune system and the fecal bacterial mass regulates 
physiologic bowel functions. The mucosal immune system 
has evolved to balance the need to respond to pathogens 
while maintaining active tolerance to commensal bacteria 
and food antigens. In IBD, this tolerance breaks down and 
infl ammation supervenes driven by the intestinal microbial 
fl ora. 
    A large part of  research has traditionally been devoted 
to finding a causative biological source of  any disease. 
This has also been the case in IBD, but to date there is no 
compelling evidence of  an etiological role for any single 
pathogenic microorganism. 
PATHOGENIC MICROBES
The history of  IBD is dotted by cyclic reports on the 
isolation of  specifi c infectious agents responsible for CD 
or UC. Several microorganisms, such as Mycobacterium 
paratuberculosis, Listeria monocytogenes, Chlamydia trachomatis, 
Escherichia coli, Cytomegalovirus, Saccharomyces cerevisiae, have 
been proposed as having a potential etiologic role.  
    The suggested etiologic role of  Mycobacterium paratuber-
culosis in CD is also controversial. This bacterium is the 
causative agent of  Johne’s disease, a chronic granuloma-
tous ileitis in ruminants, which closely resembles CD. M. 
paratuberculosis was initially isolated from CD tissues some 
20 years ago[11] and follow-up studies have tried to culture 
M. paratuberculosis for testing specific DNA sequences in 
intestinal tissues, or measuring serum antibodies against M. 
paratuberculosis with confl icting or inconclusive results[12-14]. 
Recently, M. paratuberculosis has been identified by in situ 
hybridization to the M. paratuberculosis-specifi c IS900 gene 
in tissue specimens of  Crohn’s disease[15] and in 40% of  
Crohn’s disease granulomas isolated from surgical speci-
mens by laser capture microdissection[16]. Others have 
localized M. paratuberculosis by PCR to macrophages and 
myofi broblasts within the lamina propria[17]. However, the 
possibility of  an association between M. paratuberculosis and 
CD remains inconclusive.
    Additionally, E. coli bacteria possessing special adhesive 
properties have been associated with the development of  
ulcerative colitis. 
    A fascinating hypothesis was published in the Lancet 
in 2003[18]: an association between refrigeration and CD. 
Some so called psychrotrophic bacteria are capable of  
growing slowly at low temperature (known as “cold chain 
hypothesis”). Common pathogens are Yersinia enterocolitica, 
Listeria monocytogenes, and Clostridium botulinum[19].
    Several studies have demonstrated members of  the Yersinia 
species in intestinal mucosal samples of  Crohn’s disease. 
The specifi c pathogens detected are either Y. enterocolitica 
or Y. pseudotuberculosis, and sometimes even both[20,21]. There 
are numerous aspects of  yersiniosis which resembles the 
inflammatory reaction seen in Crohn’s disease, making 
differential diagnoses of  these two conditions, including 
ileitis or ileocolitis, mesenteric adenolymphitis, reactive 
arthritis and erythema nodosa. Additionally, granulomas 
may be observed in histological samples[18].
    Recent data also demonstrate a role of  mucosa-asso-
ciated and intramucosal bacteria in the pathogenesis of  
IBD and colorectal cancer. In the study by Martin et al [22], 
mucosa-associated or intramucosal E.coli are present in 
43% and 29% of  CD, and 17% and 9% of  controls, re-
spectively, supporting a role of  mucosa-adherent bacteria 
in the pathogenesis of  Crohn’s disease.
    Finally, a viral etiology has also been proposed as the 
cause of  IBD, particularly CD. An early measle infection 
during the perinatal period notably increases the risk of  
Crohn’s disease[23]. The fi nding of  paramixovirus-like parti-
cles in CD endothelial granulomas suggests an association 
between perinatal measles and predisposition to CD based 
on some epidemiological and serologic data[24]. However, 
these preliminary findings are not confirmed by later 
studies[25]. Importantly, the progressive decline of  measle 
virus infection in the last decades with the concomitant 
rise of  CD during the same period of  time speaks against 
an etiologic role of  measles in CD. The hypothesis that 
measle vaccination rather than measle infection, might be 
a risk factor for CD, has also been raised, but again results 
of  additional studies fail to confi rm this association[26]. In 
contrast, a role of  cytomegalovirus infection is proposed 
in UC[27].
NON-PATHOGENIC INTESTINAL FLORA
In the last decade, the focus of  interest in microbial etiol-
ogy of  IBD has shifted from infectious to commensal 
agents. Based on fairly solid data, there is a substantial 
body of  evidence that the normal enteric flora plays a 
key role in the development of  IBD[28]. This is even more 
evident after the discovery of  the genetic factors (e.g. 
NOD2/CARD15, TLR4 and CD14) responsible for al-
terations in bacterial perception[29]. The benefi cial effect of  
antibiotics in the treatment of  CD, and to a lesser extent 
UC, has been appreciated for years. Diversion of  the fecal 
stream from infl amed bowel loops has also been known to 
induce symptomatic improvement in CD patients, while 
re-emergence of  infl ammation often occurs upon restora-
tion of  intestinal continuity[30]. 
    Changes are observed in the normal flora of  IBD 
patients and dysbacteriosis is commonly reported. 
Based on the clinical picture of  IBD, the intestinal fl ora 
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might play a role in the initiation and perpetuation of  
infl ammatory reaction. Fabia et al[31] demonstrated that the 
concentration of  anaerobic bacteria and Lactobacillus are 
radically decreased in active IBD patients. On the contrary, 
patients with inactive IBD show no such decrease. 
Swidsinski et al[32] compared over 300 IBD patients with 40 
control individuals and found that abnormalities can be 
observed in the fl ora using various laboratory techniques. 
In addition, a much greater number and concentration 
of  bacteria make up the biofi lms covering the epithelium 
involved in IBD. Furthermore, a direct association has also 
been reported between bacterial concentration and disease 
severity.
    More recently, probiotics (primarily lactic acid bacteria) 
defined as live microbial feeds that beneficially affects 
the host by modulating gut microbial balance, have 
been demonstrated to improve both human IBD and 
experimental colitis, primarily by preventing relapses, thus 
adding an important dimension to the role of  gut fl ora in 
IBD[33,34]. 
    Probably, the most convincing evidence comes from 
experimental data. In the majority of  IBD animal models, 
intestinal inflammation fails to develop when they are 
kept in a germfree environment. This critical observation 
has led to the widely accepted paradigm ‘‘no bacteria, no 
colitis’’. However, once normal flora is introduced into 
their environment, the mutant-strain mice quickly develop 
colitis[35, 36].
    It is worth mentioning that bacterial superinfection (most 
commonly Clostridium diffi cile, but also Entamoeba histolytica, 
Campylobacter spp, etc.) is also able to elicit relapse of  IBD. 
In the study of  Mylonaki et al[37], 10.5% of  all relapses are 
associated with enteric infections. In another study[38], 20% 
of  all relapses are correlated to C. diffi cile positivity.
    The presence of  bacterial antigens as the initiating factor 
in IBD has also been explored. The data support a role of  
fl agellin proteins in activating the innate immune system. 
Elevated titers of  serum anti-flagellin IgG against these 
proteins could be detected in CD patients[39]. Furthermore, 
elevated serum IgG2a titers could also be demonstrated in 
experimental IBD models, similar to results observed in 
humans. Recently, anti-CBir1 (anti-fl agellin) expression has 
been independently associated with small-bowel, internal-
penetrating and fi brostenosing disease features in CD[40].
    Finally, the role of  bacteria in the pathogenesis of  IBD 
is further supported by the increased intestinal perme-
ability in CD patients. Although it is not an environmental 
factor per se, it has been postulated as an early predisposing 
factor for the development of  this condition. Increased in-
testinal permeability is also observed in asymptomatic fi rst-
degree relatives of  CD patients, possibly encompassing 
another group of  individuals who are at an increased risk 
of  developing this form of  IBD[41,42]. Documented obser-
vations of  increased permeability preceding the onset of  
symptomatic disease are of  further interest[43]. In relating 
this phenomenon to the UC form, electron microscopy 
has revealed defi ciency of  those elements comprising the 
tight junctions necessary for the wholeness of  the intes-
tinal epithelium[44]. Recent data reporting an association 
between genes important in mucosal transport and integ-
rity (OCTN and DLG5) and IBD further support this as-
sumption.
    The phenomenon of  decreased bacterial diversity of  
the intestinal microflora obtained from stool samples in 
IBD patients has also been suggested, based on culture-
dependent microbiological techniques[45]. Recently, a Ger-
man group has reported the relative lack of  the Bacteroides 
group (usually accounting for 50-90% of  the anaerobic 
faecal microfl ora) by utilizing 16sDNA-based single strand 
conformation polymorphism (SSCP) fi ngerprint, cloning 
experiments and real time PCR. Moreover, the bacterial 
profi les are stable, at least for the observed period of  six 
weeks. This is in concordance with previous fi ndings, sug-
gesting that the mucosa-associated microflora contains 
only a small number of  bacteria of  the Bacteroides/Prevotella 
group[46]. However, in a recent study comparing the fae-
cal microflora of  healthy controls and CD patients, no 
differences are noted between patients and healthy con-
trols[47]. This lack of  signifi cant difference may be partially 
explained by the differences in mucosal and faecal micro-
fl ora.
    Why an abnormal response to normal endogenous gut 
bacteria exists in IBD is not clear, but recent data, espe-
cially on the genetic background of  CD, suggest an asso-
ciation between gut infl ammation and abnormal bacterial 
sensing.
GENETICS AND GENE FUNCTION
Possible genetic loci influencing the presentation of  
infl ammatory bowel disease have already been identifi ed 
on more than half  of  all chromosomes, including the X 
chromosome[48-50]. First, in 1996 Hugot et al[51] reported 
that the pericentromeric region of  chromosome 16 
(D16S408) is associated with CD renamed as IBD1[51]. 
This is confi rmed by several studies. To this date, results 
of  numerous studies have revealed a total of  nine loci 
associated with specifi c linkage requirements, subsequently 
labeled as IBD1-9[52-56] (Table 1). Furthermore, it is clear 
that some loci correlate with either UC or CD while 
others are involved in the pathogenesis of  both IBD 
forms[50].
Table 1 Locations of nine major loci showing linkage to 
infl ammatory bowel disease
IBD locus Chromosome Identifi ed genes Disease 
IBD1 16q13 NOD2/CARD15 CD
IBD2 12q14 Not known
(VDR, STAT6, MMP18, b2-integrin)
UC
IBD3 6p Not known
(HLA, TNF) 
IBD
IBD4 14q11-12 Not known
(TCR, LTB4 receptor)
CD
IBD5 5q31-33 SLC22A4/A5 CD
IBD6 19p13 Not known
(ICAM1, C3, TBXA2) 
IBD
IBD7 1p36 Not known
(TNF-R family) 
IBD
IBD8 16p12 Not known CD
IBD9 3p26 Not known
(CCR5, CCR9,hMLH1) 
IBD
10q23 DLG5 IBD
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FAMILIAL STUDIES
Evidence of  genetic constituents in the induction 
of  inflammatory bowel disease clearly lies within the 
results of  familial studies. Several studies examining the 
relationship of  IBD within families have reported positive 
fi ndings in 10-25% of  families[57,58]. This fi nding goes back 
at least two decades when Farmer and Michener reported 
40% concordance for IBD in fi rst-degree relatives. They 
observed that sibling-sibling involvement occurs in 
addition to parent-offspring transmission. 
    Solid evidence of  genetic predisposition showed that as 
many as 50% of  monozygotic twins are affected by Crohn’s 
disease whereas ulcerative colitis is seen in approximately 
14%[59]. Monozygotic twins are not equally affected but still 
display greater concordance for IBD than dizygotic twins. 
The overall risk for IBD is increased by 5-20 times[60], be-
ing highest in twins and in siblings. The genetic compo-
nent is more prominent in CD than in UC.
    Finally, genetics certainly play a role in the observed 
phenotype of  IBD, including disease behavior and loca-
tion[61]. 
    Genetic anticipation is suggested in early studies with a 
more severe and earlier presentation of  the disease in sub-
sequent generation[62], but this has not been replicated in 
more recent studies[63,64].
GENES INVOLVED IN THE RECOGNITION 
OF BACTERIA – NOD2/CARD15, NOD1/
CARD4, TLR4 AND CD14
NOD2/CARD15 
Three independent groups have identified NOD2 
CARD15 on chromosome 16 in IBD1 as a candidate gene 
for CD[29,65,66]. 
    NOD2/CARD15 is an intracellular element responsible 
for the indirect recognition of  bacterial peptidoglycan 
through the binding of  muramyl dipeptide[67,68]. It is a 
member of  the Ced4-APAF1 protein superfamily and is 
expressed in various cells, including monocytes, dendritic 
cells, Paneth cells and intestinal epithelial cells[6]. Structur-
ally, NOD2/CARD15 is composed of  three segments: the 
fi rst being composed of  two CARD units, the central por-
tion consisting of  nucleotide-binding domain (NBD) and 
finally, a leucine-rich repeat (LRR) region as is found in 
TLRs[69].  The most intriguing question that remains to be 
answered concerns the mechanism whereby mutations in 
the NOD2/CARD15 gene predispose towards the chronic 
intestinal infl ammation characteristics of  CD.
    At the molecular level, the binding of  NOD2/CARD15 
to a bacterial motif  (muraryl dipeptide-MDP, a component 
of  both Gram negative and positive bacterial cell walls) 
causes its binding to a second NOD2/CARD15 molecule, 
thus forming a dimer. Further interaction with other cy-
tosolic proteins leads to the ultimate activation of  nuclear 
factor κB (NF-κB), eliciting pro-infl ammatory reactions[69] 
(Figure 1). Surprisingly, it is still unclear whether NF-κB 
expression is elevated or depressed in CD due to confl ict-
ing observations and studies. In vitro experiments demon-
strated that the declined activity of  this protein indicates a 
loss-of-function effect[70,71]. Hisamatsu et al[72] showed that 
CARD15/NOD2 may function as an antibacterial factor 
in CaCo2 intestinal epithelial cells. Cells stably transfected 
with a wild-type CARD15/NOD2 gene construct are able 
to prevent invasion of  Salmonella typhimurium. This protec-
tive effect is lost in cells transfected with gene constructs 
of  mutant CARD15/NOD2. It has also been demon-
strated that NOD2/CARD15 expression in intestinal 
epithelial cells might be upregulated by the proinfl amma-
tory cytokine tumor necrosis factor α (TNF-α)[73]. The NF-
κB activation is regulated by the LRR region and deletion 
within this region may theoretically result in its uncon-
trolled activation. In concordance with this, increased NF-
κB activation is observed in the presence of  3020insC 
mutation by stimulation of  MDP[74], which may explain 
the fi ndings of  higher NF-κB tissue levels in samples from 
IBD patients[75]. Interestingly, mice lacking NOD2 or pos-
sessing mutated NOD2 variants do not spontaneously de-
velop Crohn’s disease. These fi ndings suggest that NOD2 
mutations create an intestinal environment susceptible to 
IBD[74,76] rather than playing a direct causative role in dis-
ease development expression of  α- and β-defensins.
    Defensins are integral parts of  the local intestinal im-
mune system, and are secreted by intestinal epithelium 
as endogenous antimicrobial proteins. The consequential 
damage could fi nally lead to an intensifi ed bacterial inva-
sion and a chronic inflammation of  the intestinal mu-
cosa[77]. The possibility exists that NOD2/CARD15 is 
involved in the regulation of  Paneth cell degranulation[78], 
as NOD2/CARD15 expression is noted in close proxim-
ity to the secretory granules of  these cells. Kobayashi et 
al[76] and Wehkamp et al[79] have shown that carriage of  
NOD2/CARD15 variants may be associated with reduced 
α-defensin release from Paneth cells in response to bac-
terial cell wall components, and the defective defensin 
release by the Paneth cells could provide the missing link, 
whereby reduced NOD2/CARD15 activity impairs host 
defenses against bacteria and underlies persistent intestinal 
infl ammation. Finally, NOD2/CARD15 is involved in the 
regulation of  TLR2 stimuli by peptidoglycans. Defective 
Figure 1 NOD2/TLR4 signaling pathway. NOD2 activation by CARD-CARD 
dimmer formation results in binding to RICK kinase (RIP-like interacting CLARP 
kinase). RICK then activates the nuclear factor kB inhibitor (IkB) kinase complex 
(IKK) via phosphorylation of IKKc. The IKK complex next phosphorylates IkB 
resulting in nuclear factor kB (NFkB) translocation to the nuclei and transcriptional 
activation of NFkB responsive genes, such as pro-inflammatory cytokines or 
defensins. TLR4 induces activation through other molecules (Myd88, IRAK and 
TRAF6).
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NOD2 function results in a pro-inflammatory cytokine 
bias after stimulation of  mononuclear cells with TLR2 
stimuli, which may contribute to the overwhelming infl am-
mation in Crohn’s disease[80].
    Three major mutations have been identified within 
NOD2/CARD15: one frame shift (3020insC, SNP13) 
and two missense mutations (R702W-SNP8 and G908R-
SNP12). 
    The presence of  NOD2/CARD15 mutations increases 
the risk for CD by 1.4-4.3-fold in heterozygous patients 
and 17.6-44.0-fold in homozygous and compound het-
erozygous patients. Reports on homozygous individuals 
who are disease-free are available. One such family has 
been described by van der Linde et al[81]. It is estimated that 
any of  these three common mutations involving NOD2/
CARD15, is present in heterozygous form in 30-50% of  
CD patients and 7-20% of  controls from North-America 
and Europe[82-86]. However, various geographical differ-
ences are noted. Furthermore, other races display a much 
lower prevalence of  this mutation, sometimes lacking it 
altogether (e.g. African-American[87], Chinese[88] and Japa-
nese[89]). The prevalence is also lower in other North Euro-
pean countries[90,91].
    The association between NOD2/CARD15 and disease 
phenotype and behavior has also been investigated. The 
three common mutations are associated with ileal disease 
and fibrostenosing behavior, but they are relatively less 
frequent in colonic and fi stulous disease[64,66,92,93]. The pres-
ence of  mutations is not associated with extraintestinal 
manifestations or the response to infliximab therapy[94]. 
The mutations are also not associated with UC. In CD, 
the attributable risk for ileal disease is 40% determined by 
NOD2/CARD15 and 20% by HLA genes. The numbers 
are similar for ileo-colonic disease (NOD2/CARD15: 
30%, HLA: 40%), while colonic disease is thought to be 
associated with HLA and other yet unknown genes[92].
    It is worth mentioning that NOD2/CARD15 increases 
the risk for colorectal cancer (CRC). Kurzawski et al[95] 
have found that the presence of  SNP13 mutation increases 
the risk of  developing CRC by 2.23-fold in patients with 
an age >50 years at diagnosis of  CRC. This has not been 
confi rmed in a more recent study by Alhopuro et al[96].
NOD1/CARD4
A similar protein to NOD2/CARD15 by its structure 
and function, is located on chromosome 7p. Its particular 
location is in the midst of  a region with strong IBD 
correlation, being translated into an intracellular bacterial 
pathogen-associated molecular pattern[97]. 
    Zouali et al[98] denounced that NOD1/CARD4 plays a 
role in IBD following an investigation involving 63 IBD 
patients. The screening process was conducted on the 
eleven exons constituting the NOD1/CARD4 gene with 
the goal of  identifying polymorphisms. Indeed, several 
variants were identified, none of  which has proved any 
association with IBD[98]. On the contrary, McGovern et 
al[97] have located a complex insertion/deletion allele on 
NOD1, associating it with both an early onset of  IBD and 
extraintestinal manifestations.
Toll-like receptors and CD14 
Toll-like receptors (TLRs) expressed in myeloid cells play a 
major role both in detecting microbes (lipopolysaccharide) 
and in initiating innate immune responses. Accordingly, a 
disturbance in its function predisposes to infections with 
Gram negative bacterial pathogens, possibly influencing 
the advancement of  IBD[99,100]. In contrast, little is known 
about the expression, distribution and function of  TLRs 
in epithelial cells per se. TLR4 is also expressed in the 
Golgi apparatus of  intestinal epithelial cells. Thus, LPS 
recognition in intestinal epithelial cells may occur in the 
Golgi apparatus and requires LPS internalization [101]. 
Recently, it has been suggested that the interaction of  LPS 
with TLR4 / MD2 contributes to the perpetuation of  
the infl ammatory epithelial cell injury via TNFα induced 
alterations of  enterocyte turnover in an autoparacrine/
paracrine manner[102]. TLRs may also infl uence the nature 
of  immune response by skewing T cells toward a Th1 or 
Th2 profi le. Myeloid cells are exquisitely sensitive to TLR 
ligands and produce signifi cant IL-12p40. They appear to 
play a key role in the initiation and possibly the Th1/Th2 
skewing of  inflammatory responses. In this model the 
inflammation can be normally controlled by myeloid or 
lymphocyte-derived IL-10 acting through Stat3 in myeloid 
cells to block further production of  IL-12/IL-23 and 
skewing the responses towards Th1 profi le[103]. 
    IBD is characterized by an altered expression pattern 
of  TLRs on the surface of  intestinal epithelium and TLR4 
expression is up-regulated in patients with CD. In contrast, 
the expressions of  TLR2 and TLR5 are unchanged, 
while TLR3 that recognizes viral replication is down- 
regulated[104]. The D299G (Asp299Gly) polymorphism of  
the TLR4 gene associated with LPS hyporesponsiveness[105] 
is associated with CD (OR:2.45-2.80) and UC (OR: 
2.05)[99,106]. However, other studies have failed to replicate 
this association[86,107].
    Another TLR which binds to and recognizes bacterial 
DNA, TLR9, may also play an important role in the 
pathogenesis of  IBD. Rachmilewitz et al[108] reported that 
the anti-infl ammatory effect of  probiotics is transmitted 
through TLR9 in experimental colitis. More recently, an 
English group has reported a synergy between TLR9 and 
NOD2 that is lost in the CD patients carrying NOD2 
mutation, indicating impairment in innate immunity[109]. 
Recently, Torok et al[110] reported that the -1237C promoter 
polymorphism of  TLR9 is signifi cantly associated with CD 
in German patients.
    Contradictory data are available on the association 
between the bacterial receptor CD14 and IBD. Klein et 
al[111] found that the 159 TT genotype is associated with 
CD but not with UC. In a Japanese study[112], the same 
genotype is associated with UC (OR: 1.96) but not with 
CD and also a further study investigating Caucasian 
patients has failed to demonstrate any association[113].
MUCOSAL INTEGRITY AND TRANSPORT - 
SLC22A4/OCTN1, SLC22A5/OCTN2 AND 
DLG5
SLC22A4/OCTN1, SLC22A5/OCTN2 
The association between 5q31 and CD is first noted in 
genome-wide screens (the genes for Th2 cytokines -e.g. 
IL-3, 4, 5, 9, 13 and IRF1- maps to this region). The 
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risk haplotype is associated only with a moderate risk 
for CD (OR: 1.4-1.5). The effect of  NOD2/CARD15 
is additive while the 5q31 haplotype is an independent 
risk factor[114-116]. A German study reported that the risk 
haplotype is also associated with UC while the IBD5 
haplotype is not associated with the clinical presentation, 
nor is it correlated to IBD in Japanese[115]. Based on the 
available data, IBD5 increases mainly the overall risk for 
IBD, whereas NOD2/CARD15 mutations are primarily 
responsible for the determination of  phenotype. 
    One of  the most important findings in the genetics 
of  IBD is the identification of  OCTN1/SLC22A4 and 
OCTN2/SLC22A5 genes coding for integral membrane 
proteins. The function of  these proteins is multispecific 
in bidirectional transmembrane transport of  carnitine and 
organic cations. The SLC22A4 C1672T and SLC22A5 
promoter G207C variants increase the risk for CD by 
2-2.5-fold when present as a single copy and by 4-fold in 
homozygous carriers[56,117].  The elevated risk attributed to 
OCTN TC haplotype and NOD2/CARD15 mutations, is 
additive with an odds ratio of  7.3-10.5 in double carriers. 
A more recent Japanese study on SLC22A4/A5 and 
DLG5 polymorphisms and CD[118], has shown a weak 
association, concurring with the Ashkenazi population[119], 
where the frequency of  the allele is lower, indicating racial 
differences. Variant alleles are associated with functional 
changes. The SLC22A4 variant encodes exchange of  a 
leucine residue on the OCTN1 transmembrane domain 
for phenylalanine (L503F), a change which reduces 
carnitine but augments organic cation transporter activity. 
The SLC22A5 variant impairs heat shock protein-driven 
promoter transcriptional activation[117]. Carnitine is an 
essential mediator of  fatty acid oxidation, a role subserved 
by promoting transport of  long-chain fatty acids across 
the mitochondrial membrane. Inhibition of  fatty acid 
oxidation can evoke clinical and pathologic signs of  
colitis[120], which may explain why impairments in carnitine 
transport may confer an increased risk for IBD. Another 
possibility is that the enhanced cation transporter activity 
of  the OCTN1 503F variant may provoke disease by 
allowing aberrant uptake of  toxic substrates.
    A possible association between OCTN3 and CD 
has been reported[121,122]. In contrast, no association has 
been found between the proton-coupled bivalent metal 
antiporter located on 2q35 SLC11A1 and IBD[123].
DLG5 
The association between DLG5 (Drosophilia Discs Large 
Homolog 5) at chromosome 10q22-23 is first reported 
by Stoll et al[124]. DLG5 is a member of  the membrane-
associated guanylate kinase (MAGUK) gene family which 
encodes cell scaffolding proteins and is also involved in 
the maintenance of  epithelial integrity and regulation of  
cell growth[125], a role potentially impaired by expression 
of  the CD-associated DLG5 variants causing increased 
permeability and disease. The impact on the overall risk of  
developing IBD is much smaller than NOD2/CARD15. 
The carriage of  the 113A allele increases the risk for CD 
by 1.3-2.1-fold in German, Italian, Canadian patients 
and is associated with early onset of  IBD in Scottish 
children[124,126,127]. Less common variants have also been 
identified (C4126A). Interaction between DLG5 and 
NOD2/CARD15 is also detectable. This however, has not 
been replicated by the same group in English and Scottish 
CD patients and by the German group from Munich[128,122].
HLA, CYTOKINE GENES AND OTHER GENETIC 
FACTORS
HLA genes 
Reports on genetic trait of  IBD are available, which 
investigated the genes associated with the immune 
response. The main region of  interest is that of  MHC (main 
histocompatibility complex) genes located on chromosome 
6. The human leukocyte antigen (HLA) class II genes are 
candidates for a role in the pathogenesis of  IBD because 
their products play a central role in the immune response. 
More than 100 known genes are located in the area, each is 
highly variable and several polymorphisms are known. 
    Several studies have addressed the possible association 
between certain HLA polymorphisms and the risk for IBD. 
Most of  these studies have revealed contradictory results 
and their findings could not be replicated in different 
populations. Overall, genes in the HLA region may play 
a greater role in modifying IBD phenotype rather than in 
determining overall disease susceptibility[129-131].
    The association of  UC with HLA genes is stronger 
than CD[4,131]. In the white Caucasian population, the rare 
HLA-DRB1*0103 allele is positively associated with UC 
(OR: 3.42). Others have found that this allele predisposes 
to extensive disease and is additionally associated with 
the presence of  extraintestinal manifestations[132]. The 
repeatedly observed association with HLA-DR2 has been 
confirmed in the cumulative odds ratio of  2.00, while 
the odds ratio for DRB1*1502 and DR9 is 3.74 and 1.54, 
respectively. In contrast, the presence of  DR4 (OR: 0.54) 
and DRw6 is preventive for UC[133].
    In CD, negative association has been found between 
DR2 (OR = 0.83) and DR3 (OR = 0.71), while HLA-
DR7 and DQ4 seem to be associated with a moderately 
increased risk (OR = 1.42 and 1.88). The studies on allele 
DRB3*0301 showed that this allele is positively associated 
with Crohn’s disease (OR = 2.18)[4,31]. Ahmad et al [92] 
investigated 340 polymorphisms in HLA genes and found 
that the 3 common NOD2/CARD15 alleles, the HLA 
DRB1*0701 (RR: 1.5) and Cw*802 (RR3.0) are associated 
with increased risk for CD, while the presence of  HLA 
DRB1*1501 (RR: 0.6) is protective.
    Investigating the genotype-phenotype relations, HLA 
DRB1*0103 allele in both UC and CD is associated with 
both extensive and severe disease as judged by the need 
for colectomy[132,134]. However, the low frequency of  this 
allele even in UC patients suggests that this association 
is unlikely to be clinically useful in predicting disease 
course. The same allele is associated with late onset, 
colonic location (38.5% vs controls 3.2%) of  CD[135], 
while the presence of  HLA-DRB1*04 (OR:1.7) and 
HLA-DRB1*0701 (OR: 1.9) increased the risk for ileal 
location[136]. MICA*010 (MHC class I chain-related gene 
A) and HLA-DRB*0103 are associated with perianal 
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disease[92].
    A number of  genetic associations have also been de-
scribed in extraintestinal manifestations of  IBD. Stud-
ies comprising both UC and CD patients showed that 
migratory pauciarticular large-joint arthritis is associated 
with HLA-DRB1*0103 and B*27 and B*35 class I al-
leles in linkage disequilibrium. In contrast, chronic small-
joint symmetric arthritis is associated with HLA-B*44[137]. 
Uveitis is correlated to HLA-B*27, B*58 and DRB1*0103, 
while erythema nodosum to B*15 and TNF-1031C[138]. 
However, due to the relatively small sample size of  these 
studies, the evidence is lacking to draw a fi rm conclusion.
Cytokine, multidrug resistance and cell adhesion gene 
polymorphisms
Interaction between non-pathogenic, commensal bacteria 
and epithelial cells, M-cells and dendritic cells of  the 
intestinal mucosa is characterized by a cytokine profile 
of  mainly the Th2/Th3 (suppressor) type (IL-4, IL-5, 
IL-10, TGF-β), which incapacitates the development 
of  an inadequate, progressive, proinflammatory cycle in 
healthy individuals[139]. Contrary to this, mucosal immune 
response against pathogenic species is largely mediated 
by Th1 cells and a specifi c cytokine milieu (IL-1, TNF-α, 
interferon-γ). Both ulcerative colitis and Crohn’s disease 
are characterized by an increased expression of  "general" 
proinflammatory cytokines (TNF-α, IL-1, IL-6), which 
suggests an abnormally intense inflammatory response 
against commensal bacteria. This loss of  immune tolerance 
to non-pathogenic microbes results in pathologic immune 
reactivity and a self-supporting infl ammatory cascade. In 
healthy individuals, the tight control of  the infl ammatory 
reaction between bowel mucosa and bacterial milieu 
involves antiinflammatory cytokines (IL-10, TGF-β)[140]. 
In case of  cytokine imbalance, the infl ammatory reaction 
intensifies. However, lack of  antiinflammatory cytokines 
plays only a restricted role in the development and 
maintenance of  IBD, which is suggested by their low 
therapeutic potential in IBD[141]. In contrast, the widely 
used chimera or humanized anti-TNF antibody represents 
one of  the most fascinating new therapeutic options in 
severe and/or penetrating CD cases as well as UC[142-144]. 
Studies are also underway targeting IL-12[145].
    Although the above mechanism is pivotal in the 
induction of  local inf lammatory changes from an 
immunological point of  view, lack of  reproducibility 
has challenged many of  the other reported genotype-
phenotype associations in IBD, such as association 
between interleukin polymorphisms and IBD.
    The association between a low-producing allele, 
allele 2 of  the interleukin (IL)-1RA gene and UC (OR: 
1.3), extensive colitis, the need for colectomy[146,147] and 
development of  pouchitis (OR: 3.1) in UC after ileal-
pouch anastomosis[148] has been reported in Caucasian 
population. However, another study investigating 529 
IBD patients has failed to confi rm these results[149]. IL-10 
polymorphisms also lack association with UC. However, 
the 627A allele is more frequent in patients with left sided 
colitis[150]. In contrast, the frequency of  the high IL-10 
producer allele (-1082*G) is decreased in IBD[151].
    Bone loss and osteoporosis are well recognized in IBD, 
but the risk factors have not been clearly identifi ed. Several 
studies investigated whether genetic markers may predict 
bone loss and found that variable number of  tandem re-
peats adjacent to IL-6 or within IL-1RA and genes previ-
ously implicated in the paracrine stimulation of  osteoclasts 
are associated with bone resorption[152]. A subsequent study 
from the same group has failed to identify an association 
with a putatively functional polymorphism in the IL-6 
gene. Nemetz et al[153] reported that the 511*2 allele of  IL-
1b is associated with increased in vitro production of  IL-1b 
by mononuclear cells in Hungarian CD patients[153].
    Furthermore, microsatellite loci of  TNF-α are associ-
ated with CD[154]. However, only data from a single study 
suggest that the TNF-308A polymorphism is associated 
with more intense infl ammatory activity and an increased 
risk of  arthritis in CD patients with fi stulizing disease[155].
    The A6 allele MICA is associated with UC and early 
onset of  disease[156], while the MICA*011 allele increases 
the risk for UC by almost 2-fold. No association has been 
found between different polymorphisms of  CTLA4, a 
receptor of  activated T cells, which has an inhibitory 
function in regulating T-cell activation and IBD in different 
Caucasian and Asian populations[157,158].
    Brant et al[159] have described a suggestive linkage on 
chromosome 7q containing the multidrug resistance 
(MDR)-1 gene, in association with the appearance of  UC 
and CD. This particular gene is a membrane transport 
protein with several documented human polymorphisms 
having effects on intestinal absorption and drug pharma-
cokinetics. The significant mutation designated as Ala-
893Ser/Thr is originally identifi ed in knockout mice with 
spontaneous colitis[160,161]. An additional locus of  mutation 
(C3435T) associated with 50% decreased protein secretion 
corresponding to UC (OR: 1.6-2.0) especially in extensive 
colitis (OR: 2.64), showed no manifestation in CD[162,163]. 
    Adhesion molecules mediating cell-cell and cell-
extracellular matrix interactions, are pivotal mediators of  
inflammation in IBD. Catenins and catherins are major 
contributors of  integrity of  the intestinal mucosa[164]. 
Dysregulation in E-cadherin-catenin complex formation 
leads to decomposit ion of  the mucosal structure 
characterized by leaky epithelium, as observed in IBD.
    Cell surface adhesion molecules conveying leukocyte-
endothelial interactions, govern homing of  activated 
inflammatory cells into the bowel mucosa. In order to 
slow down by rolling along the endothelium, circulating 
leukocytes in small vessels of  the inflamed mucosa 
interact with adhesion molecules (e.g. CD44) expressed in 
the endothelium. This is followed by establishing a firm 
adhesion anchor. Extravasation and migration into the site 
of  inflammation are mediated by integrins (mainly α4β2 
and α4β7) and selectins (L-, E- and P-selectin). Vascular 
endothelium of  the inflamed intestine, particularly in 
CD, is characterized by increased expression of  adhesion 
molecules and integrin ligands, such as E-selectin, 
ICAM-1, MAdCAM-1, VCAM-1[165,166]. In UC, the soluble 
E-selectin levels show no preference between active or in-
active forms. Also, the sVCAM concentration is far higher 
in the control group than in the inactive UC patients. Fi-
nally, unlike in CD, VEGF levels in UC cases are similar 
in active, inactive and control subjects[167]. Expression of  
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certain adhesion molecules (MAdCAM-1, CCL25) is also 
increased in tissues not primarily involved in the pathologi-
cal process of  IBD (e.g. liver), which might account for the 
extraintestinal manifestations of  the disease[168].
    Finally, in Japanese CD patients, the ICAM-1 K469 al-
lele in IBD6 is associated with CD (OR: 2.6) and UC[169]. 
This association has also been confirmed in Caucasian 
population[170]. Targeted therapy against certain adhesion 
molecules (e.g. a4 and ICAM-1) is currently one of  the 
major focuses of  pharmaceutical trials in IBD[171,172].
    In conclusion, various factors have been implicated in 
the pathogenesis of  IBD, but its mechanism of  action is 
still obscure. Recent data indicate that altered NOD2/
CARD15 (or TLR4)-mediated bacterial sensing of  normal 
commensal flora in the gut and mucosal permeability 
changes may be the key mechanisms (see Figure 2). At 
present, most efforts are devoted to a better understanding 
of  the genetic changes underlying IBD and to further 
clarifi cation of  how the altered recognition of  pathogenic 
and/or commensal microbial factors by the mucosal 
immune system leads to infl ammation in IBD subjects but 
not in the general population (Figure 3).
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